Skip to content

Author

A. Dispenzieri

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Oct 2026

Emerging therapies and translational tools for drug development in systemic amyloidosis: insights from the International Society of Amyloidosis Scientific Workshop.

BACKGROUND Amyloidosis is caused by deposition of misfolded proteins as amyloid fibrils in multiple organs. Over the past decade, disease-modifying therapies have markedly improved outcomes in both amyloid light-chain (AL) amyloidosis and amyloid transthyretin (ATTR) amyloidosis. Progress in AL amyloidosis has been dri...

Gareth J. Morgan, A. Dispenzieri, Jing Fu et al. · 0 citations
Case report Open access Sep 2026

Apolipoprotein A-IV Cardiac Amyloidosis Presenting as Massive Ventricular Wall Thickening Mimicking Hypertrophic Cardiomyopathy

Background Apolipoprotein A-IV amyloidosis (AApoAIV) is a rare systemic amyloidosis that can involve the heart and mimic hypertrophic cardiomyopathy. Case Summary A 64-year-old woman with presumed hypertrophic cardiomyopathy presented with dyspnea. Imaging showed severe left ventricular wall thickening, outflow tract o...

R. Coderre, G. Tersalvi, R. Adigun et al. · 0 citations
Review Open access Sep 2026

Phenotypic Considerations for Tafamidis Use in a Real-World Cohort of Older Patients with Transthyretin Amyloid Cardiomyopathy

Disease-modifying therapies for transthyretin amyloid cardiomyopathy (ATTR-CM) improve clinical outcomes, yet older patients are undertreated. In this analysis, we evaluated survival and cardiovascular-related hospitalizations (CVH) among patients treated with tafamidis (tafamidis free acid at 61 mg or bioequivalent ta...

C. Fumagalli, F. Cappelli, M. Maurer et al. · 0 citations
Review Open access Aug 2026

124I-Evuzamitide Positron Emission Tomography/Computed Tomography for Diagnosing Cardiac Amyloidosis: The REVEAL Nonrandomized Clinical Trial.

Results support 124I-evuzamitide PET/CT as a diagnostic test to evaluate patients with suspected cardiac amyloidosis and support 124I-evuzamitide PET/CT as a diagnostic test to evaluate patients with suspected cardiac amyloidosis.

S. Dorbala, Mathew S. Maurer, S. Cuddy et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.